PrEP for HIV Prevention
(RAPID Response Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this study is to learn whether adults who visit a hospital emergency department (ED) find it acceptable to start HIV pre-exposure prophylaxis (PrEP) during that same visit, with help from a peer navigator. PrEP is a daily pill that lowers the chance of getting HIV. Many people who could benefit from PrEP use the ED for health care but have no regular doctor, so they may never be offered it.
The main questions this study aims to answer are:
* Do participants find starting PrEP in the ED acceptable?
* How many participants take the first dose, connect with an ongoing PrEP provider, and keep taking PrEP over one year?
At Tampa General Hospital, a peer PrEP navigator (a trained study team member) will offer PrEP information to adults in the ED. Adults who agree to join the study and test HIV-negative will:
* take their first PrEP pill in the ED while the navigator watches, and leave with a 29-day supply at no cost
* choose a community PrEP provider for ongoing care, with help from the navigator
* answer short surveys before leaving the ED and by phone at 2-3 days, 30 days, 60 days, 90 days, and 1 year
* allow the navigator to confirm follow-up PrEP lab work with their outside provider at about 120 days
Who Is on the Research Team?
Bernice K McCoy, PhD, MPH
Principal Investigator
University of South Florida
Are You a Good Fit for This Trial?
This trial is for adults visiting the emergency department who test negative for HIV and are interested in starting daily medicine to prevent HIV. Participants should not already be taking PrEP or have a regular provider offering it.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
- RAPID Response peer navigation
Trial Overview
The study tests if starting PrEP (a daily pill called Emtricitabine/tenofovir) during an ER visit, with help from a peer navigator, is acceptable and helps people keep using PrEP over time. Participants get their first dose in the ER and support finding ongoing care.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Adults in the emergency department who test HIV-negative receive navigator support to start oral PrEP before discharge: first dose taken under observation, a 29-day take-home supply at no cost, help choosing a community PrEP provider, and follow-up contacts through 1 year.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of South Florida
Lead Sponsor
Tampa General Hospital
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.